Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA7QTC)

Drug Name

Lactoferrin Drug Info

Synonyms

Lactoferroxin B; Lactoferroxin-B; AC1L4UTC; Arg-tyr-tyr-gly-tyr-och3; AC1Q5JP4; methyl n5-(diaminomethylidene)-l-ornithyl-l-tyrosyl-l-tyrosylglycyl-l-tyrosinate; 117667-26-2; L-Tyrosine, N-(N-(N-(N-L-arginyl-L-tyrosyl)-L-tyrosyl)glycyl)-, methyl ester; methyl (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoate

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[1]
Discovery agent	N.A.	Investigative	[2]

Cross-matching ID

PubChem CID: 126456119
CAS Number: CAS 151186-19-5
TTD Drug ID: DMA7QTC

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tryptase alpha/beta-1 (Tryptase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[2]
APC-2059	DM8IB6K	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[3]
APC-366	DM02DNQ	Asthma	CA23	Discontinued in Phase 2	[2]
BABIM	DM8AGOE	Asthma	CA23	Terminated	[2]
BAY-17-1998	DM7LZFQ	Asthma	CA23	Terminated	[4]
BAY-44-3428	DM40ORU	Asthma	CA23	Terminated	[5]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[6]
BMS-262084	DMETNA3	Discovery agent	N.A.	Investigative	[7]
AMG-126737	DM9H7AZ	Discovery agent	N.A.	Investigative	[8]
MOL 6131	DMSF8UC	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tryptase alpha/beta-1 (Tryptase)	TTM1TDX	TRYB1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
3	Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13.
4	Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
5	Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
6	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
7	Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.
8	Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000.